Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 162

Sort by

Sort Order Select

Journal Articles

An Update of a Comparison of Nonmyeloablative Allografting with Autografting for Newly Diagnosed Myeloma.

Blood (2007) 110 (11): 482.

https://doi.org/10.1182/blood.V110.11.482.482

Published: 2007

Journal Articles

A Prospective Phase II Study on Tandem Autografting-Nonmyeloablative Allografting for Newly Diagnosed Myeloma: Final Results of the Gruppo Italiano Trapianto Midollo Osseo.

Blood (2007) 110 (11): 3026.

https://doi.org/10.1182/blood.V110.11.3026.3026

Published: 2007

Journal Articles

CMV Infection and Disease after Nonmyeloablative (NM) HCT Revisited: Incidence, Risk Factors, Ganciclovir-Related Neutropenia and Outcome.

L. Norasetthada, K. Kirby, B. Sandmaier, D. Maloney, M. Maris, C. Davis, L. Corey, R. Storb, M. Boeckh

Blood (2005) 106 (11): 3247.

https://doi.org/10.1182/blood.V106.11.3247.3247

Published: 2005

Journal Articles

Efficacy of Nonmyeloablative Hematopoietic Cell Transplant (HCT) in Secondary Myelodysplastic Syndrome (MDS) and Its Impact on the Primary Disease.

F. Kerbauy, M. Maris, B. Storer, D. Maloney, D. Niederwieser, E. Agura, M. Pulsipher, T. Chauncey, R. Maziarz, S. Forman, A. Langston, J. Wade, B. Scott, J. Deeg, R. Storb, B. M. Sandmaier

Blood (2005) 106 (11): 792.

https://doi.org/10.1182/blood.V106.11.792.792

Published: 2005

Journal Articles

Hematopoietic Cell Transplants (HCT) from HLA-Matched Related (MRD) and Unrelated (URD) Donors for Patients with Hematologic Malignancies Using Low-Dose TBI Conditioning.

Blood (2005) 106 (11): 655.

https://doi.org/10.1182/blood.V106.11.655.655

Published: 2005

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning after Failed Myeloablative HCT: Factors Affecting Outcomes.

Frederic Baron, R. Storb, B. Storer, D. Maloney, M. Maris, D. Niederwieser, J. Shizuru, T. Chauncey, B. Bruno, S. Forman, P. McSweeney, R. Maziarz, M. Pulsipher, E. Agura, M. Sorror, J. Wade, B. Sandmaier

Blood (2005) 106 (11): 1143.

https://doi.org/10.1182/blood.V106.11.1143.1143

Published: 2005

Journal Articles

Immunologic Recovery after Nonmyeloablative (NM) Conditioning: A Comparison between Related Versus Unrelated Donor Hematopoietic Cell Transplantation (HCT).

Frederic Baron, M. Maris, J. Storek, M. Metcalf, K. White, B. Sandmaier, D. Maloney, R. Storb, M. Boeckh

Blood (2005) 106 (11): 1402.

https://doi.org/10.1182/blood.V106.11.1402.1402

Published: 2005

Journal Articles

Double Autologous Transplant Versus Tandem Autologus - Non Myeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma.

Blood (2005) 106 (11): 46.

https://doi.org/10.1182/blood.V106.11.46.46

Published: 2005

Journal Articles

Donor NK Cell Engraftment and Overall and Progression-Free Survivals after Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning.

Frederic Baron, T. Gooley, M.T. Little, E. Petersdorf, M. Malkki, D. Maloney, M. Maris, P. Stroup, S. Shin, J. Baker, T. Chauncey, K. Blume, B. Sandmaier, R. Storb

Blood (2005) 106 (11): 398.

https://doi.org/10.1182/blood.V106.11.398.398

Published: 2005

Journal Articles

HLA-Matched Related (MRD) or Unrelated Donor (URD) Non-Myeloablative Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Refractory and Relapsed Aggressive Non Hodgkin Lymphoma (NHL).

L. Norasetthada, M. B. Maris, B. M. Sandmaier, T. Gooley, S. Forman, E. Agura, R. T. Maziarz, J. Shizuru, D. Niederwieser, R. Storb, D. G. Maloney

Blood (2004) 104 (11): 2307.

https://doi.org/10.1182/blood.V104.11.2307.2307

Published: 2004

Journal Articles

HLA-Matched Unrelated Donor HCT after Nonmyeloablative Conditioning for Patients with Chronic Myeloid Leukemia.

Frederic Baron, M. Maris, B. Sandmaier, B. Storer, M. Stuart, P. McSweeney, J. Radich, M. Pulsipher, E. Agura, E. Petersdorf, S. Heimfeld, T. Chauncey, M.T. Little, D. Maloney, K. Blume, R. Storb

Blood (2004) 104 (11): 2755.

https://doi.org/10.1182/blood.V104.11.2755.2755

Published: 2004

Journal Articles

Qualitative and Quantitative Molecular Follow up of Minimal Residual Disease after Non Myeloablative Allografting for Multiple Myeloma.

B. Bruno, M. Ladetto, M. Astolfi, L. Veneziano, L. Cimolin, E. Galletto, G. Pagliano, M. Rotta, N. Mordini, L. Giaccone, P. Omedè, S. Battaglio, R. Storb, M. Boccadoro

Blood (2004) 104 (11): 5128.

https://doi.org/10.1182/blood.V104.11.5128.5128

Published: 2004

Journal Articles

Feasibility and Toxicity of Nonmyeloablative Hematopoietic Cell Transplantation (HCT) with or without Imatinib for Philadelphia Chromosome (Ph+) Acute Lymphoblastic Leukemia (ALL).

L. Norasetthada, M. B. Maris, B. M. Sandmaier, D. G. Maloney, G. Georges, B. Druker, J. Radich, R. Storb

Blood (2004) 104 (11): 5056.

https://doi.org/10.1182/blood.V104.11.5056.5056

Published: 2004

Journal Articles

Reduced Incidence of Acute and Chronic Graft-versus-Host Disease (GvHD) without Increased Relapse in Patients with High-Risk Myeloid Disorders Given Thymoglobulin (THY) as Part of the Transplant Conditioning Regimen: A Dose-Finding Study.

H. Joachim Deeg, MD, F. R. Appelbaum, MD, B. Storer, PhD, M. Cassarella, B. Scott, MD, G. McDonald, MD, R. Storb, MD

Blood (2004) 104 (11): 181.

https://doi.org/10.1182/blood.V104.11.181.181

Published: 2004

Journal Articles

Unrelated Donor Peripheral Blood Stem Cell (PBSC) Transplantation Using Nonmyeloablative Conditioning and Mycophenolate Mofetil (MMF) TID Results in High Engraftment Rates.

Michael B. Maris, MD, B. M. Sandmaier, MD, B. Storer, PhD, J. Shizuru, MD, PhD, D. Maloney, MD, PhD, E. Agura, MD, PhD, D. Niederwieser, MD, M. Pulsipher, MD, R. T. Maziarz, MD, P. McSweeney, MD, J. Wade, MD, A. Langston, MD, T. Chauncey, MD, B. Bruno, MD, A. Woolfrey, MD, M.T. Little, PhD, K. Blume, MD, R. Storb, MD

Blood (2004) 104 (11): 1818.

https://doi.org/10.1182/blood.V104.11.1818.1818

Published: 2004

Journal Articles

Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age

H. J. Deeg, H. M. Shulman, J. E. Anderson, E. M. Bryant, T. A. Gooley, J. T. Slattery, C. Anasetti, A. Fefer, R. Storb, F. R. Appelbaum

Blood (2000) 95 (4): 1188–1194.

https://doi.org/10.1182/blood.V95.4.1188.004k38_1188_1194

Published: 2000

Journal Articles

Long-Term Follow-up of a Randomized Study Comparing Cyclophosphamide and Total Body Irradiation With Busulfan and Cyclophosphamide for Patients Receiving Allogeneic Marrow Transplants During Chronic Phase of Chronic Myeloid Leukemia

R.A. Clift, J. Radich, F.R. Appelbaum, P. Martin, M.E.D. Flowers, H.J. Deeg, R. Storb, E.D. Thomas

Blood (1999) 94 (11): 3960–3962.

https://doi.org/10.1182/blood.V94.11.3960a

Published: 1999

Journal Articles

Long-Term Follow-Up of a Randomized Trial of Two Irradiation Regimens for Patients Receiving Allogeneic Marrow Transplants During First Remission of Acute Myeloid Leukemia

R.A. Clift, C.D. Buckner, F.R. Appelbaum, K.M. Sullivan, R. Storb, E.D. Thomas

Blood (1998) 92 (4): 1455–1456.

https://doi.org/10.1182/blood.V92.4.1455

Published: 1998

Journal Articles

Marrow Transplantation for Chronic Myeloid Leukemia: The Influence of Plasma Busulfan Levels on the Outcome of Transplantation

Blood (1997) 89 (8): 3055–3060.

https://doi.org/10.1182/blood.V89.8.3055

Published: 1997

Journal Articles

Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy

WI Bensinger, CD Buckner, K Shannon-Dorcy, S Rowley, FR Appelbaum, M Benyunes, R Clift, P Martin, T Demirer, R Storb, M Lee, G Schiller

Blood (1996) 88 (11): 4132–4138.

https://doi.org/10.1182/blood.V88.11.4132.4132

Published: 1996

NARROW

An Update of a Comparison of Nonmyeloablative Allografting with Autografting for Newly Diagnosed Myeloma.

A Prospective Phase II Study on Tandem Autografting-Nonmyeloablative Allografting for Newly Diagnosed Myeloma: Final Results of the Gruppo Italiano Trapianto Midollo Osseo.

CMV Infection and Disease after Nonmyeloablative (NM) HCT Revisited: Incidence, Risk Factors, Ganciclovir-Related Neutropenia and Outcome.

Efficacy of Nonmyeloablative Hematopoietic Cell Transplant (HCT) in Secondary Myelodysplastic Syndrome (MDS) and Its Impact on the Primary Disease.

Hematopoietic Cell Transplants (HCT) from HLA-Matched Related (MRD) and Unrelated (URD) Donors for Patients with Hematologic Malignancies Using Low-Dose TBI Conditioning.

Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning after Failed Myeloablative HCT: Factors Affecting Outcomes.

Immunologic Recovery after Nonmyeloablative (NM) Conditioning: A Comparison between Related Versus Unrelated Donor Hematopoietic Cell Transplantation (HCT).

Double Autologous Transplant Versus Tandem Autologus - Non Myeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma.

Donor NK Cell Engraftment and Overall and Progression-Free Survivals after Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning.

HLA-Matched Related (MRD) or Unrelated Donor (URD) Non-Myeloablative Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Refractory and Relapsed Aggressive Non Hodgkin Lymphoma (NHL).

HLA-Matched Unrelated Donor HCT after Nonmyeloablative Conditioning for Patients with Chronic Myeloid Leukemia.

Qualitative and Quantitative Molecular Follow up of Minimal Residual Disease after Non Myeloablative Allografting for Multiple Myeloma.

Feasibility and Toxicity of Nonmyeloablative Hematopoietic Cell Transplantation (HCT) with or without Imatinib for Philadelphia Chromosome (Ph+) Acute Lymphoblastic Leukemia (ALL).

Reduced Incidence of Acute and Chronic Graft-versus-Host Disease (GvHD) without Increased Relapse in Patients with High-Risk Myeloid Disorders Given Thymoglobulin (THY) as Part of the Transplant Conditioning Regimen: A Dose-Finding Study.

Unrelated Donor Peripheral Blood Stem Cell (PBSC) Transplantation Using Nonmyeloablative Conditioning and Mycophenolate Mofetil (MMF) TID Results in High Engraftment Rates.

Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age

Long-Term Follow-up of a Randomized Study Comparing Cyclophosphamide and Total Body Irradiation With Busulfan and Cyclophosphamide for Patients Receiving Allogeneic Marrow Transplants During Chronic Phase of Chronic Myeloid Leukemia

Long-Term Follow-Up of a Randomized Trial of Two Irradiation Regimens for Patients Receiving Allogeneic Marrow Transplants During First Remission of Acute Myeloid Leukemia

Marrow Transplantation for Chronic Myeloid Leukemia: The Influence of Plasma Busulfan Levels on the Outcome of Transplantation

Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only